Tao Fu, Attovia Therapeutics CEO

At­tovia reels in $105M from crossover in­vestors to run mul­ti­ple tri­als of I&I bi­o­log­ics

Cal­i­for­nia biotech At­tovia Ther­a­peu­tics is back with a $105 mil­lion Se­ries B just 11 months af­ter un­veil­ing with $60 mil­lion.

The Fre­mont …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.